Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on SELLAS Life Sciences Group (SLS – Research Report). The associated price target remains the same with $4.00.
Jason McCarthy’s rating is based on the promising advancements SELLAS Life Sciences Group has made in its clinical trials and financial positioning. The company has shown significant progress in its Phase 3 REGAL study of Galinpepimut-S (GPS) for acute myeloid leukemia (AML), with positive interim analysis results suggesting a favorable outcome compared to historical benchmarks. Additionally, the ongoing Phase 2a study of their CDK9 inhibitor, SLS009, has demonstrated impressive overall response rates and median overall survival in patients, surpassing pre-specified targets.
Furthermore, SELLAS has strengthened its financial runway with a recent $25 million equity financing, providing sufficient capital to support operations into 2026. This financial stability, combined with the anticipated data releases from their ongoing trials, positions the company well to unlock further value. McCarthy’s valuation model, which includes a risk-adjusted revenue forecast and a discounted cash flow analysis, supports a 12-month price target of $4.00, reflecting the potential upside from these developments.
According to TipRanks, McCarthy is an analyst with an average return of -17.5% and a 27.88% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group, Medicus Pharma Ltd, and Actinium Pharmaceuticals.